Cargando…
PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787437/ https://www.ncbi.nlm.nih.gov/pubmed/36568449 http://dx.doi.org/10.4103/iju.iju_229_22 |